Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

Clinical-Scale Production of CAR-T Cells for the Treatment of Melanoma Patients by mRNA Transfection of a CSPG4-Specific CAR under Full GMP Compliance.

Wiesinger M, März J, Kummer M, Schuler G, Dörrie J, Schuler-Thurner B, Schaft N.

Cancers (Basel). 2019 Aug 16;11(8). pii: E1198. doi: 10.3390/cancers11081198.

2.

Enhancing lentiviral transduction to generate melanoma-specific human T cells for cancer immunotherapy.

Simon B, Harrer DC, Thirion C, Schuler-Thurner B, Schuler G, Uslu U.

J Immunol Methods. 2019 Sep;472:55-64. doi: 10.1016/j.jim.2019.06.015. Epub 2019 Jun 14.

PMID:
31207210
3.

Arming T Cells with a gp100-Specific TCR and a CSPG4-Specific CAR Using Combined DNA- and RNA-Based Receptor Transfer.

Simon B, Harrer DC, Schuler-Thurner B, Schuler G, Uslu U.

Cancers (Basel). 2019 May 20;11(5). pii: E696. doi: 10.3390/cancers11050696.

4.

Generation of an Oncolytic Herpes Simplex Virus 1 Expressing Human MelanA.

Boscheinen JB, Thomann S, Knipe DM, DeLuca N, Schuler-Thurner B, Gross S, Dörrie J, Schaft N, Bach C, Rohrhofer A, Werner-Klein M, Schmidt B, Schuster P.

Front Immunol. 2019 Jan 22;10:2. doi: 10.3389/fimmu.2019.00002. eCollection 2019.

5.

Automated closed-system manufacturing of human monocyte-derived dendritic cells for cancer immunotherapy.

Erdmann M, Uslu U, Wiesinger M, Brüning M, Altmann T, Strasser E, Schuler G, Schuler-Thurner B.

J Immunol Methods. 2018 Dec;463:89-96. doi: 10.1016/j.jim.2018.09.012. Epub 2018 Sep 25.

PMID:
30266448
6.

The Generation of CAR-Transfected Natural Killer T Cells for the Immunotherapy of Melanoma.

Simon B, Wiesinger M, März J, Wistuba-Hamprecht K, Weide B, Schuler-Thurner B, Schuler G, Dörrie J, Uslu U.

Int J Mol Sci. 2018 Aug 11;19(8). pii: E2365. doi: 10.3390/ijms19082365.

7.

Hypertonicity-enforced BCL-2 addiction unleashes the cytotoxic potential of death receptors.

Sirtl S, Knoll G, Trinh DT, Lang I, Siegmund D, Gross S, Schuler-Thurner B, Neubert P, Jantsch J, Wajant H, Ehrenschwender M.

Oncogene. 2018 Jul;37(30):4122-4136. doi: 10.1038/s41388-018-0265-5. Epub 2018 Apr 30.

8.

The siRNA-mediated downregulation of PD-1 alone or simultaneously with CTLA-4 shows enhanced in vitro CAR-T-cell functionality for further clinical development towards the potential use in immunotherapy of melanoma.

Simon B, Harrer DC, Schuler-Thurner B, Schaft N, Schuler G, Dörrie J, Uslu U.

Exp Dermatol. 2018 Jul;27(7):769-778. doi: 10.1111/exd.13678.

PMID:
29704887
9.

Hypertonicity primes malignant melanoma cells for apoptosis.

Calance DN, Steixner C, Gross S, Schuler-Thurner B, Knoll G, Ehrenschwender M.

Apoptosis. 2018 Apr;23(3-4):201-209. doi: 10.1007/s10495-018-1446-y.

PMID:
29435687
10.

Good Manufacturing Practice-Compliant Production and Lot-Release of Ex Vivo Expanded Regulatory T Cells As Basis for Treatment of Patients with Autoimmune and Inflammatory Disorders.

Wiesinger M, Stoica D, Roessner S, Lorenz C, Fischer A, Atreya R, Neufert CF, Atreya I, Scheffold A, Schuler-Thurner B, Neurath MF, Schuler G, Voskens CJ.

Front Immunol. 2017 Oct 26;8:1371. doi: 10.3389/fimmu.2017.01371. eCollection 2017.

11.

Survival of metastatic melanoma patients after dendritic cell vaccination correlates with expression of leukocyte phosphatidylethanolamine-binding protein 1/Raf kinase inhibitory protein.

Buschow SI, Ramazzotti M, Reinieren-Beeren IMJ, Heinzerling LM, Westdorp H, Stefanini I, Beltrame L, Hato SV, Ellebaek E, Gross S, Nguyen VA, Weinlich G, Ragoussis J, Baban D, Schuler-Thurner B, Svane IM, Romani N, Austyn JM, De Vries IJM, Schuler G, Cavalieri D, Figdor CG.

Oncotarget. 2017 Jun 27;8(40):67439-67456. doi: 10.18632/oncotarget.18698. eCollection 2017 Sep 15.

12.

Comparison of the Serum Tumor Markers S100 and Melanoma-inhibitory Activity (MIA) in the Monitoring of Patients with Metastatic Melanoma Receiving Vaccination Immunotherapy with Dendritic Cells.

Uslu U, Schliep S, Schliep K, Erdmann M, Koch HU, Parsch H, Rosenheinrich S, Anzengruber D, Bosserhoff AK, Schuler G, Schuler-Thurner B.

Anticancer Res. 2017 Sep;37(9):5033-5037.

PMID:
28870930
13.

Preclinical evaluation of NF-κB-triggered dendritic cells expressing the viral oncogenic driver of Merkel cell carcinoma for therapeutic vaccination.

Gerer KF, Erdmann M, Hadrup SR, Lyngaa R, Martin LM, Voll RE, Schuler-Thurner B, Schuler G, Schaft N, Hoyer S, Dörrie J.

Ther Adv Med Oncol. 2017 Jul;9(7):451-464. doi: 10.1177/1758834017712630. Epub 2017 Jun 13.

14.

Sarcoidosis Under Dendritic Cell Vaccination Immunotherapy in Long-term Responding Patients with Metastatic Melanoma.

Uslu U, Erdmann M, Schliep S, Dörrie J, Schaft N, Schuler G, Schuler-Thurner B.

Anticancer Res. 2017 Jun;37(6):3243-3248.

PMID:
28551671
15.

Twelve-year survival and immune correlates in dendritic cell-vaccinated melanoma patients.

Gross S, Erdmann M, Haendle I, Voland S, Berger T, Schultz E, Strasser E, Dankerl P, Janka R, Schliep S, Heinzerling L, Sotlar K, Coulie P, Schuler G, Schuler-Thurner B.

JCI Insight. 2017 Apr 20;2(8). pii: 91438. doi: 10.1172/jci.insight.91438. eCollection 2017 Apr 20.

16.

Block Excision of Iridociliary Tumors Enables Molecular Profiling and Immune Vaccination.

Heindl LM, Koch KR, Hermann MM, Merkelbach-Bruse S, Schultheis AM, Wagener S, Büttner R, Mauch C, Schuler-Thurner B, Schuler G, Cursiefen C.

Ophthalmology. 2017 Feb;124(2):268-270. doi: 10.1016/j.ophtha.2016.09.011. Epub 2016 Oct 27. Review. No abstract available.

PMID:
28195057
17.

Immunotherapy of Uveal Melanoma: Vaccination Against Cancer.

Kummer M, Schuler-Thurner B.

Methods Mol Biol. 2017;1499:273-278.

PMID:
27987156
18.

Proteasomes generate spliced epitopes by two different mechanisms and as efficiently as non-spliced epitopes.

Ebstein F, Textoris-Taube K, Keller C, Golnik R, Vigneron N, Van den Eynde BJ, Schuler-Thurner B, Schadendorf D, Lorenz FK, Uckert W, Urban S, Lehmann A, Albrecht-Koepke N, Janek K, Henklein P, Niewienda A, Kloetzel PM, Mishto M.

Sci Rep. 2016 Apr 6;6:24032. doi: 10.1038/srep24032.

19.

[Immunotherapy of uveal melanoma: vaccination against cancer. Multicenter adjuvant phase 3 vaccination study using dendritic cells laden with tumor RNA for large newly diagnosed uveal melanoma].

Schuler-Thurner B, Bartz-Schmidt KU, Bornfeld N, Cursiefen C, Fuisting B, Grisanti S, Heindl LM, Holbach L, Keserü M, Knorr H, Koch K, Kruse F, Meiller R, Metz C, Meyer-ter-Vehn T, Much M, Reinsberg M, Schliep S, Seitz B, Schuler G, Süsskind D, Viestenz A, Wagenfeld L, Zeschnigk M.

Ophthalmologe. 2015 Dec;112(12):1017-21. doi: 10.1007/s00347-015-0162-z. German.

PMID:
26602097
20.

Stability and activity of MCSP-specific chimeric antigen receptors (CARs) depend on the scFv antigen-binding domain and the protein backbone.

Krug C, Birkholz K, Paulus A, Schwenkert M, Schmidt P, Hoffmann N, Hombach A, Fey G, Abken H, Schuler G, Schuler-Thurner B, Dörrie J, Schaft N.

Cancer Immunol Immunother. 2015 Dec;64(12):1623-35. doi: 10.1007/s00262-015-1767-4. Epub 2015 Oct 29.

PMID:
26515978
21.

Combined cytotoxic activity of an infectious, but non-replicative herpes simplex virus type 1 and plasmacytoid dendritic cells against tumour cells.

Thomann S, Boscheinen JB, Vogel K, Knipe DM, DeLuca N, Gross S, Schuler-Thurner B, Schuster P, Schmidt B.

Immunology. 2015 Oct;146(2):327-38. doi: 10.1111/imm.12509.

22.

A new method to monitor antigen-specific CD8+ T cells, avoiding additional target cells and the restriction to human leukocyte antigen haplotype.

Prommersberger S, Höfflin S, Schuler-Thurner B, Schuler G, Schaft N, Dörrie J.

Gene Ther. 2015 Jun;22(6):516-20. doi: 10.1038/gt.2015.15. Epub 2015 Mar 19.

PMID:
25786872
23.

Concurrent interaction of DCs with CD4(+) and CD8(+) T cells improves secondary CTL expansion: It takes three to tango.

Hoyer S, Prommersberger S, Pfeiffer IA, Schuler-Thurner B, Schuler G, Dörrie J, Schaft N.

Eur J Immunol. 2014 Dec;44(12):3543-59. doi: 10.1002/eji.201444477. Epub 2014 Oct 27.

24.

Effectiveness and tolerability of ipilimumab: experiences from 198 patients included in a named-patient program in various daily-practice settings and multiple institutions.

Eigentler TK, Schlaak M, Hassel JC, Loquai C, Stoffels I, Gutzmer R, Pätzold S, Mohr P, Keller U, Starz H, Ulrich J, Tsianakas A, Kähler K, Hauschild A, Janssen E, Schuler-Thurner B, Weide B, Garbe C.

J Immunother. 2014 Sep;37(7):374-81. doi: 10.1097/CJI.0000000000000046.

PMID:
25075567
25.

Immunogenic and tolerogenic effects of the chimeric IL-2-diphtheria toxin cytocidal agent Ontak® on CD25+ cells.

Lutz MB, Baur AS, Schuler-Thurner B, Schuler G.

Oncoimmunology. 2014 Mar 17;3:e28223. eCollection 2014.

26.

A GMP-compliant protocol to expand and transfect cancer patient T cells with mRNA encoding a tumor-specific chimeric antigen receptor.

Krug C, Wiesinger M, Abken H, Schuler-Thurner B, Schuler G, Dörrie J, Schaft N.

Cancer Immunol Immunother. 2014 Oct;63(10):999-1008. doi: 10.1007/s00262-014-1572-5. Epub 2014 Jun 18.

PMID:
24938475
27.

Ocular diseases in metastatic cutaneous melanoma: review of 108 consecutive patients in two German tertiary centers.

Grajewski RS, Schuler-Thurner B, Mauch C, Kreuzberg N, Koch KR, Bergua A, Cursiefen C, Heindl LM.

Graefes Arch Clin Exp Ophthalmol. 2014 Apr;252(4):679-85. doi: 10.1007/s00417-013-2563-5. Epub 2014 Jan 22.

PMID:
24449136
28.

Denileukin diftitox (ONTAK) induces a tolerogenic phenotype in dendritic cells and stimulates survival of resting Treg.

Baur AS, Lutz MB, Schierer S, Beltrame L, Theiner G, Zinser E, Ostalecki C, Heidkamp G, Haendle I, Erdmann M, Wiesinger M, Leisgang W, Gross S, Pommer AJ, Kämpgen E, Dudziak D, Steinkasserer A, Cavalieri D, Schuler-Thurner B, Schuler G.

Blood. 2013 Sep 26;122(13):2185-94. doi: 10.1182/blood-2012-09-456988. Epub 2013 Aug 19.

PMID:
23958949
29.

The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network.

Voskens CJ, Goldinger SM, Loquai C, Robert C, Kaehler KC, Berking C, Bergmann T, Bockmeyer CL, Eigentler T, Fluck M, Garbe C, Gutzmer R, Grabbe S, Hauschild A, Hein R, Hundorfean G, Justich A, Keller U, Klein C, Mateus C, Mohr P, Paetzold S, Satzger I, Schadendorf D, Schlaeppi M, Schuler G, Schuler-Thurner B, Trefzer U, Ulrich J, Vaubel J, von Moos R, Weder P, Wilhelm T, Göppner D, Dummer R, Heinzerling LM.

PLoS One. 2013;8(1):e53745. doi: 10.1371/journal.pone.0053745. Epub 2013 Jan 14.

30.

Anti-cytotoxic T-cell lymphocyte antigen-4-induced regression of spinal cord metastases in association with renal failure, atypical pneumonia, vision loss, and hearing loss.

Voskens C, Cavallaro A, Erdmann M, Dippel O, Kaempgen E, Schuler G, Schuler-Thurner B, Heinzerling L.

J Clin Oncol. 2012 Nov 20;30(33):e356-7. doi: 10.1200/JCO.2011.41.4359. Epub 2012 Oct 8. No abstract available.

PMID:
23045571
31.

RNA-stabilized whole blood samples but not peripheral blood mononuclear cells can be stored for prolonged time periods prior to transcriptome analysis.

Debey-Pascher S, Hofmann A, Kreusch F, Schuler G, Schuler-Thurner B, Schultze JL, Staratschek-Jox A.

J Mol Diagn. 2011 Jul;13(4):452-60. doi: 10.1016/j.jmoldx.2011.03.006.

32.

Frequency of circulating Tregs with demethylated FOXP3 intron 1 in melanoma patients receiving tumor vaccines and potentially Treg-depleting agents.

de Vries IJ, Castelli C, Huygens C, Jacobs JF, Stockis J, Schuler-Thurner B, Adema GJ, Punt CJ, Rivoltini L, Schuler G, Coulie PG, Lucas S.

Clin Cancer Res. 2011 Feb 15;17(4):841-8. doi: 10.1158/1078-0432.CCR-10-2227. Epub 2010 Dec 21.

33.

Targeting of DEC-205 on human dendritic cells results in efficient MHC class II-restricted antigen presentation.

Birkholz K, Schwenkert M, Kellner C, Gross S, Fey G, Schuler-Thurner B, Schuler G, Schaft N, Dörrie J.

Blood. 2010 Sep 30;116(13):2277-85. doi: 10.1182/blood-2010-02-268425. Epub 2010 Jun 21.

PMID:
20566893
34.

Towards a standardized protocol for the generation of monocyte-derived dendritic cell vaccines.

Erdmann M, Schuler-Thurner B.

Methods Mol Biol. 2010;595:149-63. doi: 10.1007/978-1-60761-421-0_9.

PMID:
19941110
35.

Dendritic cell vaccines in metastasized malignant melanoma.

Erdmann M, Schuler-Thurner B.

G Ital Dermatol Venereol. 2008 Aug;143(4):235-50. Review.

PMID:
18833080
36.

Functions of Anti-MAGE T-cells induced in melanoma patients under different vaccination modalities.

Connerotte T, Van Pel A, Godelaine D, Tartour E, Schuler-Thurner B, Lucas S, Thielemans K, Schuler G, Coulie PG.

Cancer Res. 2008 May 15;68(10):3931-40. doi: 10.1158/0008-5472.CAN-07-5898.

37.

A single chain immunotoxin, targeting the melanoma-associated chondroitin sulfate proteoglycan, is a potent inducer of apoptosis in cultured human melanoma cells.

Schwenkert M, Birkholz K, Schwemmlein M, Kellner C, Kügler M, Peipp M, Nettelbeck DM, Schuler-Thurner B, Schaft N, Dörrie J, Ferrone S, Kämpgen E, Fey GH.

Melanoma Res. 2008 Apr;18(2):73-84. doi: 10.1097/CMR.0b013e3282f7c8f9.

38.

Effective clinical-scale production of dendritic cell vaccines by monocyte elutriation directly in medium, subsequent culture in bags and final antigen loading using peptides or RNA transfection.

Erdmann M, Dörrie J, Schaft N, Strasser E, Hendelmeier M, Kämpgen E, Schuler G, Schuler-Thurner B.

J Immunother. 2007 Sep;30(6):663-74.

PMID:
17667530
39.

Tumor-reactive CD4+ T cell responses to the melanoma-associated chondroitin sulphate proteoglycan in melanoma patients and healthy individuals in the absence of autoimmunity.

Erfurt C, Sun Z, Haendle I, Schuler-Thurner B, Heirman C, Thielemans K, van der Bruggen P, Schuler G, Schultz ES.

J Immunol. 2007 Jun 15;178(12):7703-9.

40.

Digital karyotyping reveals frequent inactivation of the dystrophin/DMD gene in malignant melanoma.

Körner H, Epanchintsev A, Berking C, Schuler-Thurner B, Speicher MR, Menssen A, Hermeking H.

Cell Cycle. 2007 Jan 15;6(2):189-98. Epub 2007 Jan 19.

PMID:
17314512
41.

Retrospective interactive rigid fusion of (18)F-FDG-PET and CT. Additional diagnostic information in melanoma patients.

Römer W, Nömayr A, Greess H, Fiedler E, Platsch G, Schuler-Thurner B, Pfahlberg A, Hothorn T, Schuler G, Hornegger J, Bautz W, Kuwert T.

Nuklearmedizin. 2006;45(2):88-95.

PMID:
16547570
42.

Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG.

Schadendorf D, Ugurel S, Schuler-Thurner B, Nestle FO, Enk A, Bröcker EB, Grabbe S, Rittgen W, Edler L, Sucker A, Zimpfer-Rechner C, Berger T, Kamarashev J, Burg G, Jonuleit H, Tüttenberg A, Becker JC, Keikavoussi P, Kämpgen E, Schuler G; DC study group of the DeCOG.

Ann Oncol. 2006 Apr;17(4):563-70. Epub 2006 Jan 17.

PMID:
16418308
43.

[Vaccination therapy of melanoma].

Schuler-Thurner B, Schuler G.

J Dtsch Dermatol Ges. 2005 Aug;3(8):630-45. Review. German. No abstract available.

PMID:
16033483
44.

Efficient elutriation of monocytes within a closed system (Elutra) for clinical-scale generation of dendritic cells.

Berger TG, Strasser E, Smith R, Carste C, Schuler-Thurner B, Kaempgen E, Schuler G.

J Immunol Methods. 2005 Mar;298(1-2):61-72. Erratum in: J Immunol Methods. 2005 Aug;303(1-2):152.

PMID:
15847797
45.

A polyclonal anti-vaccine CD4 T cell response detected with HLA-DP4 multimers in a melanoma patient vaccinated with MAGE-3.DP4-peptide-pulsed dendritic cells.

Zhang Y, Renkvist N, Sun Z, Schuler-Thurner B, Glaichenhaus N, Schuler G, Boon T, van der Bruggen P, Colau D.

Eur J Immunol. 2005 Apr;35(4):1066-75.

46.

Differences in phenotype and function between spontaneously occurring melan-A-, tyrosinase- and influenza matrix peptide-specific CTL in HLA-A*0201 melanoma patients.

Maczek C, Berger TG, Schuler-Thurner B, Schultz ES, Hamann A, Dunbar PR, Cerundolo V, Steinkasserer A, Schuler G.

Int J Cancer. 2005 Jun 20;115(3):450-5.

47.

A phase I vaccination study with tyrosinase in patients with stage II melanoma using recombinant modified vaccinia virus Ankara (MVA-hTyr).

Meyer RG, Britten CM, Siepmann U, Petzold B, Sagban TA, Lehr HA, Weigle B, Schmitz M, Mateo L, Schmidt B, Bernhard H, Jakob T, Hein R, Schuler G, Schuler-Thurner B, Wagner SN, Drexler I, Sutter G, Arndtz N, Chaplin P, Metz J, Enk A, Huber C, Wölfel T.

Cancer Immunol Immunother. 2005 May;54(5):453-67. Epub 2004 Dec 31.

PMID:
15627214
48.

MAGE-A3 is a frequent tumor antigen of metastasized melanoma.

Roeder C, Schuler-Thurner B, Berchtold S, Vieth G, Driesch Pv, Schuler G, Lüftl M.

Arch Dermatol Res. 2005 Jan;296(7):314-9. Epub 2004 Nov 27.

PMID:
15570431
49.

Inhibition of immunosuppressive effects of melanoma-inhibiting activity (MIA) by antisense techniques.

Jachimczak P, Apfel R, Bosserhoff AK, Fabel K, Hau P, Tschertner I, Wise P, Schlingensiepen KH, Schuler-Thurner B, Bogdahn U.

Int J Cancer. 2005 Jan 1;113(1):88-92.

50.

Circulation and homing of melanoma-reactive T cells to both cutaneous and visceral metastases after vaccination with monocyte-derived dendritic cells.

Berger TG, Haendle I, Schrama D, Lüftl M, Bauer N, Pedersen LØ, Schuler-Thurner B, Hohenberger W, Straten Pt Pt, Schuler G, Becker JC.

Int J Cancer. 2004 Aug 20;111(2):229-37.

Supplemental Content

Loading ...
Support Center